Suppliers / Smaart Pharmaceutticals

Smaart Pharmaceutticals

32 employees Updated 9 July 2026

Smaart Pharmaceutticals is an API manufacturer. It holds 2 active US drug master files across a filed portfolio of 2 molecules. Customs aggregates show $677K of exports covering 75 molecules to 20 destinations in 2025.

2
active US DMFs
0
valid CEPs
0
registered plants
0
filings across 0 regulators

What they file, and where

Molecule Regulators Docs
Chlorhexidine US FDA 1
Nebivolol US FDA 1

Also appears on these molecule pages

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $238K 11
2025 Not reported $677K 20
2024 Not reported $524K 18
2023 Not reported $811K 21

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Smaart Pharmaceutticals comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
Customs aggregates
Export values, molecule and destination counts